TLSA
Tiziana Life Sciences LtdPress releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-06-25 |
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary Progressive Multiple Sclerosis BOSTON, June 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. |
| 2026-06-15 |
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, |
| 2026-05-28 |
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that it will present at the Jefferies Global Healthcare Conference |
| 2026-05-21 |
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that patient enrollment has been completed in its randomized, |
| 2026-05-19 |
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue. BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 |
| 2026-05-14 |
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System Atrophy BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully |
| 2026-04-16 |
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralumab, for Long COVID associated “brain fog”. BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. |
| 2026-04-14 |
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that a late-breaking poster on its Phase 2a study of intranasal |
| 2026-04-01 |
Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces positive preclinical data highlighting nasal anti-CD3’s potential |
| 2026-02-25 |
Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces positive new biomarker data from a late-breaking poster titled |
Past events
| Date | Event | Type |
|---|---|---|
| 2025-12-16 | Annual General Meeting 2025 | Event |
| 2025-12-16 | Annual General Meeting 2025 | Event |
| 2024-12-12 | Annual General Meeting 2024 | Event |
| 2024-12-12 | Annual General Meeting 2024 | Event |
| 2023-12-14 | Annual General Meeting 2023 | Event |
| 2023-12-14 | Annual General Meeting 2023 | Event |
| 2023-06-05 | Tiziana Life Sciences: Foralumab Update in Non-Active Secondary Progressive Multiple Sclerosis (na SPMS) | Event |
| 2023-01-09 | Biotech Showcase | Event |
| 2022-12-29 | Annual General Meeting 2022 | Event |
| 2022-11-10 | Investor call | Event |
| 2022-06-14 | Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention | Event |
| 2022-04-27 | Tiziana Life Sciences to Present at the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference | Conference |
| 2022-03-14 | Tiziana Life Sciences KOL Event - Foralumab Clinical Update in Multiple Sclerosis; A Landmark Study with Intranasal Immunotherapy featuring 4 Key Opinion Leaders | Event |